Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

company partners, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.  In addition to the releasable polymer technology, Nektar is the first company to create a permanent small molecule-polymer conjugate with enhanced oral bioavailability and restricted entry into the CNS.  Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas.  Nektar recently entered into an exclusive worldwide license agreement with AstraZeneca for its oral NKTR-118 program to treat opioid-induced constipation and its NKTR-119 program for the treatment of pain without constipation side effects.  NKTR-102 is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers.  NKTR-105 is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect Nektar's current views regarding the potential of Nektar's technology platform, the potential of NKTR-102 for breast cancer patients, and preliminary results from the Phase 2 clinical trial of NKTR-102 in metastatic breast cancer.  These forward-looking statements involve substantial risks and uncertainties, including but not limited to one or more of the following: (i) NKTR-102 is in mid-stage clinical development and the risk of failur
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
(Date:8/29/2014)... , Aug. 29, 2014  Pacific Medical Data ... new website design . The main website, along ... showcases the company,s new services and content relevant to ... a new streamlined design, viewers can now better understand ... health care practices and create a more visible platform ...
(Date:8/29/2014)... Research and Markets  has announced the addition of ... 2014-2018" report to their offering. ... connect, support, or surround bones. There are several types ... fascia, and other fibrous tissues. Repetitive use, accidents, injuries, ... in wear and tear in these tissues. Orthopedic soft ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3PMDS Announces New Website 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
(Date:8/31/2014)... 2014 NutriGold announces that its ... organic fruits and berries, has been approved ... tested, including purity and label claims. , ... Acid from genetically modified and chemically produced corn ... process involves the use of a genetically modified ...
(Date:8/31/2014)... 2014 Market Research Report on ... is a professional and in-depth market survey on ... report firstly reviews the basic information of Cell ... technology. , The report then explores global and ... their product specification, capacity, production value, and market ...
(Date:8/31/2014)... finds that invisible blood in urine may be an early ... for clinicians. , Scientists at the University of Exeter ... age of 60 who had invisible blood in their urine ... bladder cancer. The figure was around half those who had ... of bladder cancer. However, it was still higher than figures ...
(Date:8/31/2014)... August 31, 2014 Adults in the U.S. ... insurance coverage can now use the Quotes Pros website as ... this year can help consumers to find and compare costs ... use of the search tool this year is expected to ... different coverage plans at various price points. The strength of ...
(Date:8/31/2014)... 2014 According to an article posted in ... Times Stronger than Heroin , a new opiate has begun ... more potent than heroin. Known as acetyl fentanyl, this opiate ... many overdoses and emergency room visits among opiate addicts because ... individual might demonstrate the signs of a heroin overdose, they ...
Breaking Medicine News(10 mins):Health News:NutriGold’s Organic Wholefood-Sourced Vitamin C Gets ConsumerLab’s Seal of Approval 2Health News:NutriGold’s Organic Wholefood-Sourced Vitamin C Gets ConsumerLab’s Seal of Approval 3Health News:Cell Harvesting System Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Cell Harvesting System Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Cell Harvesting System Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Invisible blood in urine may indicate bladder cancer 2Health News:Life Insurance Quotes Tool Installed for Public Use at New Insurer Portal Website 2Health News:New Street Drug Found to be Much More Powerful Than Heroin 2Health News:New Street Drug Found to be Much More Powerful Than Heroin 3
... Brompton and Harefield NHS Trust,s Leadership Role in the Treatment ... ... Stereotaxis, Inc. (Nasdaq:,STXS) announced that British Prime Minister Gordon Brown presided ... lab at,Royal Brompton Hospital in London. The new lab features Stereotaxis ...
... Federal Rule Changes ... Tools, CHICAGO, June 24 Allscripts, the ... physicians use,to improve healthcare, announced today that it ... Hospital Presbyterian in Newport Beach,Calif. preferred pricing on ...
... Go Healthy, Inc. (Pink,Sheets: GOHE) announced today that ... based in Myakka, Florida. Under the terms of,the agreement, ... marketing and,sales related services designed to bring awareness of ... specifics outlined in the agreement,are as follows:, -- ...
... on Top Industry ... Challenges, LAS ... change, healthcare chief financial officers feel the need to,anticipate change and begin ... CFOs face daunting challenges,and their insights on the state of the industry ...
... SARASOTA, Fla., June 24 The following statement was,issued today ... no convincing evidence that early screening,detection, and treatment improve ... include potential adverse health ... and treatment side effects." Policy Statement from ...
... the open-access journal PLoS Neglected Tropical Diseases ... Asia, and Latin America are also occurring frequently among ... and children. These diseases the "neglected infections ... parasitic, bacterial, and congenital infections. , While most ...
Cached Medicine News:Health News:London's Royal Brompton Hospital Opens New Electrophysiology Lab With State of the Art Magnetic Technology to Treat Arrhythmias 2Health News:London's Royal Brompton Hospital Opens New Electrophysiology Lab With State of the Art Magnetic Technology to Treat Arrhythmias 3Health News:Hoag Memorial Hospital Presbyterian Selects Allscripts for Electronic Health Record Subsidy Program 2Health News:Hoag Memorial Hospital Presbyterian Selects Allscripts for Electronic Health Record Subsidy Program 3Health News:Go Healthy Signs Marketing Contract with AIM Marketing 2Health News:Intersection of Financial and Regulatory Forces is Broadening Roles of Healthcare CFOs 2Health News:Intersection of Financial and Regulatory Forces is Broadening Roles of Healthcare CFOs 3Health News:Diagnostic Center for Disease: Robotic Prostatectomy - A Race to Failure? 2Health News:Diagnostic Center for Disease: Robotic Prostatectomy - A Race to Failure? 3Health News:Diagnostic Center for Disease: Robotic Prostatectomy - A Race to Failure? 4Health News:'Neglected infections of poverty' in US disable hundreds of thousands of Americans annually 2
Supplied sterile in peel-open packages. Intended for one-time use....
Used for percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
Used for percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
... Olympuss extensive line of affordable, high-quality ... our high-performance light sources to provide optimal ... light weight and durable design give you ... effectively and efficiently. And each is fully-autoclavable ...
Medicine Products: